Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2008-001339-37-IT
EUCTR2008-001339-37-IT
Active, not recruiting
Not Applicable

Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesis

AZIENDA OSPEDALIERA S. MARIA DI TERNI0 sites560 target enrollmentAugust 10, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsEMEND*2CPS 80MG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
AZIENDA OSPEDALIERA S. MARIA DI TERNI
Enrollment
560
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 10, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
AZIENDA OSPEDALIERA S. MARIA DI TERNI

Eligibility Criteria

Inclusion Criteria

  • •\- patients submitted for the first time to cisplatin chemotherapy administered in single dose
  • •\- patients over 18 years old that signed informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- patients submitted on days 2\-4 after cisplatin to other antineoplastic agents except 5\-fluorouracil, VP16, VM26, vincristine, vinblastine, vindesine, vinorelbine, gemcitabine
  • •\- patients already submitted to cisplatin
  • •\- patients with serious disease or with predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, hypercalemia and brain metastases
  • •\- patients with contraindications to dexamethasone administration (i.e. active peptic ulcer, previous blooding from peptic ulcer
  • •\- patients receiving concomitant radiotherapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Curcumin in the prevention of cisplatin-induced acute nephrotoxicityephrotoxicity.Other acute kidney failureN17.8
IRCT20180722040556N8Esfahan University of Medical Sciences100
Completed
Not Applicable
Feasibility study of the combination of cisplatin and docetaxel with concurrent thoracic radiotherapy for locally advanced resectable non-small cell lung cancer.ocally advanced resectable non-small-cell lung cancer
JPRN-UMIN000008130Hamamatsu University School of Medicine3
Completed
Phase 3
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomiting
IRCT20200819048455N1Iran University of Medical Sciences85
Not yet recruiting
Not Applicable
A study to evaluate cisplatin induced hearing loss among patients of head and neck cancers receiving chemoradiation treatmentHealth Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
CTRI/2024/08/072465Sri Venkateshwara Institute of medical sciences
Completed
Not Applicable
acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal InsufficiencyRenal insufficiencyUrological and Genital Diseases
ISRCTN43635237Academic Medical Centre (AMC) (Netherlands)246